| scholarly article | Q13442814 |
| P2093 | author name string | Marshall R Posner | |
| Christopher Lewis | |||
| Lisa A Cavacini | |||
| Mark Duval | |||
| Xiaocong Yu | |||
| Rijian Wang | |||
| Melissa A Gawron | |||
| P2860 | cites work | The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies | Q44429835 |
| Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia | Q44486781 | ||
| Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects | Q44499821 | ||
| Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. | Q44530442 | ||
| Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group | Q45752474 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells | Q46976285 | ||
| Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. | Q52025108 | ||
| Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans | Q55883944 | ||
| Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies | Q56896403 | ||
| Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men | Q57997551 | ||
| Cross-Clade HIV-1–Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1–Exposed, Persistently Seronegative Subjects | Q57997566 | ||
| Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers | Q57997576 | ||
| Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate | Q57997600 | ||
| HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals | Q57997711 | ||
| Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base | Q73149534 | ||
| Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model | Q79367320 | ||
| Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals | Q81109508 | ||
| The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling | Q27617445 | ||
| Human antibody-Fc receptor interactions illuminated by crystal structures | Q28252414 | ||
| Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya | Q28296715 | ||
| IgG Fc receptors | Q29615378 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes | Q30706865 | ||
| Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides | Q33560772 | ||
| A novel human IgA monoclonal antibody protects against tuberculosis | Q33800841 | ||
| Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals | Q33823853 | ||
| Immunoglobulin A-mediated protection against Bordetella pertussis infection | Q34008531 | ||
| IgA antibodies for cancer therapy | Q34288908 | ||
| Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy | Q34647680 | ||
| Immune complex-mediated antigen presentation induces tumor immunity | Q34793164 | ||
| Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women | Q35093052 | ||
| Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells | Q35879840 | ||
| Neutralization of HIV by milk expressed antibody | Q36492710 | ||
| Neutralizing antibodies in mucosal secretions: IgG or IgA? | Q37017811 | ||
| Toward an AIDS vaccine | Q37158259 | ||
| Humoral immunity to HIV-1: neutralisation and antibody effector functions | Q37311967 | ||
| Immunoglobulin A: A next generation of therapeutic antibodies? | Q37892323 | ||
| Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy | Q39528565 | ||
| Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. | Q39593092 | ||
| Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex | Q39593524 | ||
| The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain | Q40130304 | ||
| Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors | Q40432649 | ||
| Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals | Q40621708 | ||
| Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. | Q40762424 | ||
| Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. | Q40807309 | ||
| Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). | Q40856082 | ||
| Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers | Q40902380 | ||
| Comparative role of immunoglobulin A in protective immunity against the Bordetellae | Q42413095 | ||
| Isolation and determination of activity of IgA1 protease from Neisseria meningitidis | Q43102082 | ||
| A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils | Q43112430 | ||
| HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers | Q43976669 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 205-210 | |
| P577 | publication date | 2012-11-26 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. | |
| P478 | volume | 190 |
| Q98623621 | A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction |
| Q37833671 | A novel whole-bacterial enzyme linked-immunosorbant assay to quantify Chlamydia trachomatis specific antibodies reveals distinct differences between systemic and genital compartments |
| Q41355686 | APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. |
| Q35058860 | Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. |
| Q40410573 | Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. |
| Q33865785 | Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy |
| Q38799374 | Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. |
| Q52332235 | Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. |
| Q64905315 | Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract. |
| Q28831255 | Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition |
| Q62487341 | Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1 |
| Q38284611 | Re-thinking the functions of IgA(+) plasma cells |
| Q26752274 | Recent Advances in Clinical Glycoproteomics of Immunoglobulins (Igs) |
| Q52648924 | Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. |
Search more.